Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer (NCT04918810) | Clinical Trial Compass
TerminatedPhase 2
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
Stopped: Recruitment lower than expected. The proportion of patients with mGSTPi undetectable prior to chemo. was significantly higher than anticipated. Decision made to close due to insufficient patient numbers to able to obtain meaningful data collection.
Australia6 participantsStarted 2022-07-29
Plain-language summary
The purpose of this study is to see if a prostate cancer marker in the blood (mGSTP1) can be used to guide chemotherapy treatment. Based on the level of this blood marker, some people may be able to have breaks in treatment rather than having chemotherapy continuously which is the current standard of care. This study will tell us if having these treatment breaks guided by mGSTP1 can improve how people feel during treatment while still treating the prostate cancer effectively.
Docetaxel is a chemotherapy drug that is approved to treat prostate cancer and has been used for many years to treat prostate cancer like yours. Your doctor has already discussed this with you and you have both agreed that docetaxel is the best treatment for you to have at this time. You will have already started this chemotherapeutic treatment with docetaxel.
Who can participate
Age range18 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient has provided written informed consent using the GUIDE pre-screening PICF
✓. Age ≥ 18 years at the time of pre-screening consent
✓. Males with metastatic castration-resistant prostate cancer (as per PCWG3) AND are planned to commence docetaxel chemotherapy
✓. WHO Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix 1)
✓. Histological confirmation of prostate cancer
✓. Patients must have adequate bone marrow and hepatic function within 14 days prior Cycle 1 day 1:
✓. Willing and able to comply with all pre-screening study requirements, including blood tests for mGSTP1 analysis before and during docetaxel treatment
Exclusion criteria
✕. Prior docetaxel or cabazitaxel chemotherapy for castration-resistant prostate cancer
✕. Prior docetaxel in the castration sensitive prostate cancer setting within the previous 2 years
What they're measuring
1
Radiographic progression free survival (rPFS)
Timeframe: From enrollment until last patient has completed 2 years in follow up, on average 3.5 years
Trial details
NCT IDNCT04918810
SponsorAustralian and New Zealand Urogenital and Prostate Cancer Trials Group
✕. Known hypersensitivity to docetaxel or its excipients
✕. Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety
✕. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol
✕. Patient has provided written informed consent for the main GUIDE study PICF
✕. Patient has a detectable plasma mGSTP1 deoxyribonucleic acid (DNA) as measured by central laboratory at prescreening prior to commencing first cycle of docetaxel chemotherapy